AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). This variety can make management challenging. Comorbidities, an individual’s history, toxicities, medication availability and cost, and patient preferences should all be considered in the process of informed decision making.
Tweet Content
Metformin Reduces Osteoarthritis Risk
Metformin may help cut the risk of osteoarthritis (OA) in those with type 2 diabetes, researchers reported.
https://t.co/dmyKssbWjO https://t.co/p7lPdjYfbU
Links
Spondyloarthritis Innovations The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, espec
Tweet Content
Spondyloarthritis Innovations
The second day of RheumNow Live 2023 ended with a focus on axial spondyloarthritis, especially on the evaluation of the definition of the disease, the inheritance of it, and of course the treatment of it.
https://t.co/3JeNeE0EO6 https://t.co/fA1B2TA2xF
Links
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell u
Tweet Content
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links
FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira - but adalimumab-adaz HCF wont be available in
Tweet Content
FDA Approves Citrate-Free Formulation of Hyrimoz, a Biosimilar to Humira - but adalimumab-adaz HCF wont be available in USA until July 1, 2023 https://t.co/RRjxPW5I4O https://t.co/hf6NlkGG7W
Links
Polypharmacy Increased in Psoriatic Arthritis Psoriatic arthritis (PsA) is plagued by obesity, depression and increase
Tweet Content
Polypharmacy Increased in Psoriatic Arthritis
Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.
https://t.co/vispc9ei51 https://t.co/s45Nmpf46P
Links
A Pilot Trial of Anifrolumab in Discoid Lupus A research report in JAMA Dermatology describes the use of the type 1 in
Tweet Content
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/8OZqRvD1Lv https://t.co/T7dWQWc1gX
Links